Moreover, the spotting-lethal rats, which carry a naturally occurring deletion in the endothelin ET B receptor gene, were utilized to examine effects of genetic deficiency for this receptor subtype. Two weeks after balloon injury, the ratio of neointimal to medial area (neointima/media ratio) was determined. Treatment with A-192621 (30 mg/kg/day) for two weeks after injury significantly increased neointima/media ratio in the injured artery. In contrast, ABT-627 (10 mg/kg/day) and J-104132 (10 mg/kg/day) markedly decreased neointima/media ratio to the same extent. Furthermore, neointima/media ratio in the injured artery of ET B -deficient rat was significantly increased compared with that of wild-type rat, and this increase was abolished by treatment with J-104132. These findings suggest that the inhibition of ET B receptor system leads to an aggravation of neointimal hyperplasia after balloon injury and the augmentation of ET A -mediated actions are responsible for the neointimal hyperplasia aggravated by the pharmacological blockade of ET B receptor or by its genetic deficiency. The antagonism of the ET A receptor system is essential for preventing the restenosis after angioplasty.
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Introduction
Balloon angioplasty and stenting are now widely used for the treatment of coronary arterial disease. While these procedures improve regional myocardial blood flow by dilating stenotic coronary vessels, one major drawback of this therapeutic approach is the restenosis after procedure, due to vascular smooth muscle cells (VSMCs) proliferation and neointimal formation triggered by mechanical endothelial injury. Recently, drug-eluting stents releasing antimitotics (sirolimus and paclitaxel) has reduced the incidence of restenosis (Erglis et al., 2007; Moses et al., 2003) , but JPET #157065 6 approach. Moreover, the spotting-lethal (sl) rat, which carries a naturally occurring deletion in the endothelin ET B receptor gene, was utilized to examine effects of genetic deficiency for this receptor subtype. Because homozygous (sl/sl) rats do not live beyond 1 month of age due to intestinal aganglionosis and resulting intestinal obstruction, dopamine β-hydroxylase (DβH) promoter was used to direct ET B transgene expression in sl/sl rats to support normal enteric nervous system development. These transgenic sl/sl rats live into adulthood and are healthy, expressing ET B receptors in the adrenal glands and other adrenergic neurons.
However they are ET B -deficient in other tissue, with the most important factor being ET B receptor deficiency in the vascular endothelium and vascular smooth muscle (Gariepy et al., 1998; Gariepy et al., 2000) . This ET B receptor-deficient rat is a useful tool in determining the pathophysiological roles of ET B receptors in the vascular system. This article has not been copyedited and formatted. The final version may differ from this version.
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Methods
Animals. Two series of experiments were carried out. In the first series to investigate the pathological role of ET B receptors by pharmacological blockade, male Sprague-Dawly (SD) rats (Japan SLC, Shizuoka, Japan) were used. In the second series, male ET B receptor-deficient (sl/sl) and wild-type (+/+) rats were used. The creation of transgenic sl/sl rats has been described previously (Gariepy et al., 1998) .
Homozygous (sl/sl) rats have dark eyes and pigmented coats only in small spots on their heads. Wild-type and heterozygous rats have pigmented heads, backs, and tails.
To definitively differentiate these rats, polymerase chain reaction was performed on DNA isolated from tail biopsy specimens, as described (Gariepy et al., 1998) . The animals were housed in a light-controlled room with a 12-h light/dark cycle and were allowed ad libitum access to food and water. Experimental protocols and animal care methods in the experiments were approved by the Experimental Animal Committee at Osaka University of Pharmaceutical Sciences. lamina, and external elastic lamina were traced and measured the neointimal and medial area. The ratio of neointimal to medial area (neointima/media ratio) was calculated dividing neointimal area by medial area.
Drugs.
A-192621 
Results
Neointimal Hyperplasia after Balloon Injury and Effects of Pharmacological
Blockade. There were no significant differences in body weight and SBP among all groups (Table 1) .
Neointimal formation was not observed in the uninjured arteries of each group (Figs. 1A-1D ). In the injured arteries, there was thickening of neointima in each group.
The extent of neointimal hyperplasia was more pronounced in A-192621-treated rat than in vehicle-treated rat. In contrast, ABT-627-and J-104132-treated rats exhibited reduced neointimal hyperplasia (Figs. 1E-1H). Figs. 2A and 2C ). There were no significant differences in the medial area all of the groups (Fig. 2B ).
Neointimal Hyperplasia after Balloon Injury and Effects of J-104132 in
ET B -deficient Rats. As shown in ± 3 mmHg). J-104132 did not affect SBP in both wild-type and ET B -deficient rats (Table 2 ).
In the uninjured arteries, neointimal formation was not observed in both wild-type and ET B -deficient rats (Figs. 3A and 3D). In the injured arteries, neointimal thickening were observed and the extent of neointimal hyperplasia was more marked in ET B -deficient rat than in wild-type rat ( 
Effects of Hydralazine on SBP and Neointimal Hyperplasia in ET B -deficient
This article has not been copyedited and formatted. The final version may differ from this version. rats. Hydralazine treatment decreased SBP of the ET B -deficient rats (116 ± 6 mmHg) to the same levels found in wild-type rats (Table 2) . However, hydralazine treatment did not affect neointimal area (0.202 ± 0.055 mm 2 ) and neointima/media ratio (1.411 ± 0.334), and these data remained higher than those of wild-type rats (Figs. 4A and 4C).
Effects of ET Antagonists on Plasma ET-1 Level. Figure 5A shows results of plasma ET-1 level in ET antagonist-treated SD rats. Compared with vehicle-treated rats, ET-1 level of A-192621-treated rats was significantly increased (0.402 ± 0.079 pg/ml vs. 9.564 ± 2.257 pg/ml). ABT-627-treated rats exhibited no significant differences in ET-1 level compared with vehicle-treated rats (0.402 ± 0.079 pg/ml vs.
2.199 ± 0.719 pg/ml). J-104132-treated rats exhibited significantly increased ET-1 level compared with vehicle-treated rats (0.402 ± 0.079 pg/ml vs. 22.019 ± 1.751 pg/ml) (Fig. 5A ).
Figure 5B shows results of plasma ET-1 level in wild-type and ET B -deficient rats.
Compared with vehicle-treated wild-type rats, ET-1 level of vehicle-treated ET B -deficient rats was significantly increased (0.560 ± 0.092 pg/ml vs. 5.920 ± 1.197 pg/ml). J-104132-treated wild-type rats exhibited significantly increased ET-1 level compared with vehicle-treated wild-type rats (0.560 ± 0.092 pg/ml vs. 71.161 ± 7.110 pg/ml). J-104132-treated ET B -deficient rats also exhibited significantly increased ET-1 level compared with vehicle-treated ET B -deficient rats (5.920 ± 1.197 pg/ml vs.
85.151 ± 5.280 pg/ml) (Figs.5B).
This article has not been copyedited and formatted. The final version may differ from this version. 
